Kymera names Elizabeth Laws to lead KT-621 as Phase 2b AD trial completes enrollment
KYMR•Kymera Therapeutics has named Elizabeth Laws, Ph.D., with over 20 years of immunology R&D and commercialization leadership, as Senior Vice President and global program team leader for KT-621, its first-in-class oral STAT6 degrader. Enrollment in the Phase 2b atopic dermatitis trial is complete, asthma trial is ongoing, with topline data due by year-end 2026 and late 2027, and Phase 3 AD studies planned for mid-2027.
1. Appointment Details and Background
Kymera has appointed Elizabeth Laws, Ph.D., as Senior Vice President and global program team leader for its KT-621 development. Dr. Laws brings more than two decades of leadership in immunology clinical development, launch readiness and global commercialization, including guiding dupilumab’s expansion across dermatology, respiratory and gastroenterology indications at Sanofi.
2. KT-621 Program Timelines
The KT-621 program has completed enrollment in its Phase 2b atopic dermatitis trial, with an asthma Phase 2b study currently enrolling. Topline data for atopic dermatitis are expected by year-end 2026 and for asthma by late 2027, with registrational Phase 3 trials in atopic dermatitis slated to begin by mid-2027.
3. Strategic Development and Commercial Prospects
In her new role, Dr. Laws will oversee global strategy for KT-621, aiming to leverage targeted protein degradation to address Type 2 inflammatory diseases. Her track record of building blockbuster immunology franchises positions Kymera to advance KT-621 toward potential market leadership as an oral STAT6 degrader therapy.
